Health Canada Approves Drug to Slow Alzheimer’s Disease
On 25 October 2025, Health Canada approved lecanemab (brand name Leqembi) for use in Canada. This is the first medication in more than a decade—and the first in Canada with a mechanism of action targeting the underlying biology of Alzheimer’s disease. Lecanemab is indicated for people diagnosed with early-stage Alzheimer’s disease or mild cognitive impairment […]
